Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topotecan + VX-970 in Small Cell Cancers
NCT02487095Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2015
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of berzosertib in small cell lung cancer (SCLC) and extrapulmonary small cell carcinoma (EPSCC) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose, Clinical Response Rate and 1 more. Started Jul 2015; status: completed.
02
Drugs
berzosertib
03
Conditions
small cell lung cancer (SCLC)extrapulmonary small cell carcinoma (EPSCC)
Beyond the preview
Go deeper on NCT02487095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02487095.